Following doxorubicin treatment, compared to SIRT1 ablation, SIRT1 WT complementation significantly attenuated the reduction in cell growth, whereas SIRT1 KR complementation led to only marginal attenuation of the doxorubicin-mediated reduction in cell growth, suggesting the important role of SIRT1 ISGylation in negatively regulating doxorubicin-mediated inhibition of lung cancer cell proliferation. Here, SIRT1 is linked to lung carcinoma.